Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

Phase II Study of Pemetrexed + Cetuximab + Cisplatin With Concurrent Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and pemetrexed) with concurrent radiotherapy.

Inclusion Criteria:

• non-squamous stage III non-small cell lung cancer
• measurable disease (RECIST 1.1)
• ECOG performance status 0-1
• normal organ and marrow function

Exclusion Criteria:

• prior chest radiation therapy
• history of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma in situ of the cervix) within the last five years.
• Prior therapy with known specific inhibitors of the EGFR.
• history of severe allergic reaction to prior therapy with monoclonal antibodies